JPWO2020020281A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020020281A5
JPWO2020020281A5 JP2020552889A JP2020552889A JPWO2020020281A5 JP WO2020020281 A5 JPWO2020020281 A5 JP WO2020020281A5 JP 2020552889 A JP2020552889 A JP 2020552889A JP 2020552889 A JP2020552889 A JP 2020552889A JP WO2020020281 A5 JPWO2020020281 A5 JP WO2020020281A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
antibody
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020552889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532058A (ja
JP7524065B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/097665 external-priority patent/WO2020020281A1/zh
Publication of JP2021532058A publication Critical patent/JP2021532058A/ja
Publication of JPWO2020020281A5 publication Critical patent/JPWO2020020281A5/ja
Priority to JP2024027487A priority Critical patent/JP2024063083A/ja
Application granted granted Critical
Publication of JP7524065B2 publication Critical patent/JP7524065B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020552889A 2018-07-25 2019-07-25 抗tigit抗体及びその使用 Active JP7524065B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024027487A JP2024063083A (ja) 2018-07-25 2024-02-27 抗tigit抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810823583 2018-07-25
CN201810823583.6 2018-07-25
PCT/CN2019/097665 WO2020020281A1 (zh) 2018-07-25 2019-07-25 抗tigit抗体及其用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024027487A Division JP2024063083A (ja) 2018-07-25 2024-02-27 抗tigit抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2021532058A JP2021532058A (ja) 2021-11-25
JPWO2020020281A5 true JPWO2020020281A5 (enrdf_load_stackoverflow) 2022-07-28
JP7524065B2 JP7524065B2 (ja) 2024-07-29

Family

ID=69181312

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020552889A Active JP7524065B2 (ja) 2018-07-25 2019-07-25 抗tigit抗体及びその使用
JP2024027487A Withdrawn JP2024063083A (ja) 2018-07-25 2024-02-27 抗tigit抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024027487A Withdrawn JP2024063083A (ja) 2018-07-25 2024-02-27 抗tigit抗体及びその使用

Country Status (12)

Country Link
US (1) US11370837B2 (enrdf_load_stackoverflow)
EP (1) EP3838289A4 (enrdf_load_stackoverflow)
JP (2) JP7524065B2 (enrdf_load_stackoverflow)
KR (1) KR20210040827A (enrdf_load_stackoverflow)
CN (1) CN112135626B (enrdf_load_stackoverflow)
AU (1) AU2019310803B2 (enrdf_load_stackoverflow)
BR (1) BR112021001201A2 (enrdf_load_stackoverflow)
CA (1) CA3092456C (enrdf_load_stackoverflow)
SG (1) SG11202100746WA (enrdf_load_stackoverflow)
TW (1) TWI754157B (enrdf_load_stackoverflow)
WO (1) WO2020020281A1 (enrdf_load_stackoverflow)
ZA (1) ZA202100676B (enrdf_load_stackoverflow)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230057899A1 (en) 2019-12-05 2023-02-23 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
WO2021147854A1 (zh) * 2020-01-21 2021-07-29 信达生物制药(苏州)有限公司 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途
CN114507284B (zh) * 2020-05-09 2023-05-26 华博生物医药技术(上海)有限公司 抗tigit的抗体、其制备方法和应用
PH12022553257A1 (en) 2020-06-02 2024-02-19 Arcus Biosciences Inc Antibodies to tigit
EP4168118A1 (en) 2020-06-18 2023-04-26 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Tigit及cd112r阻斷
WO2022063100A1 (zh) * 2020-09-22 2022-03-31 南京圣和药业股份有限公司 抗tigit抗体及双抗体和它们的应用
TWI815220B (zh) * 2020-11-23 2023-09-11 大陸商廣東菲鵬制藥股份有限公司 抗tigit抗體或其抗原結合片段及其生產方法與應用,以及包含其的核酸、載體、細胞、藥物組合物及試劑盒
KR20220082776A (ko) * 2020-12-10 2022-06-17 주식회사 유틸렉스 항-tigit 항체 및 이의 용도
JP2024514974A (ja) * 2021-04-26 2024-04-03 メモリアル スローン-ケタリング キャンサー センター Adgre2及び/またはclec12aを標的とするキメラ受容体及びその使用
KR102500845B1 (ko) * 2021-05-10 2023-02-17 메디맵바이오 주식회사 항-tigit 항체 및 이의 용도
JP2024527049A (ja) 2021-07-28 2024-07-19 ジェネンテック, インコーポレイテッド がんを治療するための方法及び組成物
KR20240043786A (ko) * 2021-08-09 2024-04-03 바이오세우스 인크. 항-tigit 항체 및 이의 용도
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023108609A1 (en) * 2021-12-17 2023-06-22 Shanghai Nigene Biological Science And Technology Co., Ltd. Tigit antibodies and uses thereof
WO2023125941A1 (zh) * 2021-12-31 2023-07-06 南京维立志博生物科技有限公司 Tigit单域抗体以及基于其的双特异性抗体
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
AU2023264591A1 (en) 2022-05-02 2024-11-07 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
JP2025523387A (ja) 2022-06-07 2025-07-23 ジェネンテック, インコーポレイテッド 抗pd-l1アンタゴニストおよび抗tigitアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Il—18bp拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
GB9108652D0 (en) 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
CA2144043C (en) 1992-09-16 2005-01-18 Dennis R. Burton Human neutralizing monoclonal antibodies to respiratory syncytial virus
JP3919830B2 (ja) 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−1組換え抗体および該抗体をコードする遺伝子断片
WO1995018634A1 (en) 1994-01-04 1995-07-13 The Scripps Research Institute Human monoclonal antibodies to herpes simplex virus and methods therefor
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3369999A (en) 1998-04-02 1999-10-25 Genentech Inc. Antibody variants and fragments thereof
GB9814383D0 (en) 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
WO2000005266A1 (en) 1998-07-21 2000-02-03 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anti hepatitis c virus antibody and uses thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
SE0401751L (sv) 2004-07-05 2005-11-15 Svensk Roekgasenergi Intressen Förfarande och anordning för avskiljning av föroreningar ur ett gasflöde
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2006247591B2 (en) 2005-05-12 2011-12-15 Zymogenetics, Inc. Compositions and methods for modulating immune responses
JP5933894B2 (ja) 2007-09-14 2016-06-15 アディマブ, エルエルシー 合理的に設計された、合成抗体ライブラリおよびその使用
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
RU2598248C2 (ru) 2009-04-02 2016-09-20 Роше Гликарт Аг Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab
CA2757931C (en) 2009-04-07 2019-03-26 Roche Glycart Ag Trivalent, bispecific antibodies
WO2010136172A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
WO2012009568A2 (en) 2010-07-16 2012-01-19 Adimab, Llc Antibody libraries
HRP20201404T1 (hr) 2013-07-16 2020-11-27 F. Hoffmann - La Roche Ag Postupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita
CR20160500A (es) 2014-03-31 2016-12-14 Genentech Inc Anticuerpos anti-ox40 y métodos de uso
IL250583B (en) * 2014-08-19 2022-07-01 Merck Sharp & Dohme Anti-tigit antibodies
SG10202006538TA (en) 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
TWI715587B (zh) * 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Tigit結合劑和彼之用途
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
JP6976241B2 (ja) * 2015-08-14 2021-12-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗tigit抗体
CN108137691B (zh) * 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
CN113956358A (zh) * 2015-09-25 2022-01-21 豪夫迈·罗氏有限公司 抗tigit抗体和使用方法
RU2020124191A (ru) * 2015-10-01 2020-08-27 Потенза Терапевтикс, Инк. Анти-tigit антиген-связывающие белки и способы их применения
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
JP7109382B2 (ja) * 2016-03-04 2022-07-29 ジェイエヌ バイオサイエンシーズ エルエルシー Tigitに対する抗体

Similar Documents

Publication Publication Date Title
JPWO2020020281A5 (enrdf_load_stackoverflow)
JP2023002562A5 (enrdf_load_stackoverflow)
RU2017145150A (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
JP2020048564A5 (enrdf_load_stackoverflow)
JP2018508188A5 (enrdf_load_stackoverflow)
WO2014089209A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
JP2018526981A5 (enrdf_load_stackoverflow)
JPWO2019173420A5 (enrdf_load_stackoverflow)
JPWO2019175216A5 (enrdf_load_stackoverflow)
RU2012103212A (ru) Tlr3 связывающие агенты
WO2015191934A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
GB2595379A (en) Anti-BTLA antibodies
JPWO2019246110A5 (enrdf_load_stackoverflow)
RU2019135404A (ru) Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний
JPWO2022044573A5 (enrdf_load_stackoverflow)
JPWO2022114163A5 (enrdf_load_stackoverflow)
JPWO2020102777A5 (enrdf_load_stackoverflow)
JPWO2021133723A5 (enrdf_load_stackoverflow)
CN105131117A (zh) 靶向HER2的人源化改造的可内化单链抗体P1h2及应用
JPWO2022067262A5 (enrdf_load_stackoverflow)
JPWO2021170068A5 (enrdf_load_stackoverflow)
JPWO2022256563A5 (enrdf_load_stackoverflow)
CN115279791A (zh) 靶向her2的抗原结合构建体及用途
JPWO2022051591A5 (enrdf_load_stackoverflow)
JPWO2020003210A5 (enrdf_load_stackoverflow)